Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 59Pancreatic Neoplasms 33Colonic Neoplasms 31Rectal Neoplasms 30Stomach Neoplasms 22Neoplasm Metastasis 19Carcinoma, Non-Small-Cell Lung 19Neoplasms 16Unspecified Adult Solid Tumor, Protocol Specific 15Esophageal Neoplasms 12Ovarian Neoplasms 8Gallbladder Neoplasms 7Appendiceal Neoplasms 7Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Lung Neoplasms 6Carcinoma, Renal Cell 6Breast Neoplasms 6Bile Duct Neoplasms 6Peritoneal Neoplasms 5Liver Neoplasms 5Gastrointestinal Neoplasms 5Carcinoma, Hepatocellular 5Adenocarcinoma 5Triple Negative Breast Neoplasms 4Recurrence 4Fallopian Tube Neoplasms 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Pancreatic Ductal 4Squamous Cell Carcinoma of Head and Neck 3

Interventions

trifluridine tipiracil drug combination 1tipiracil 1andecaliximab 1Trifluridine 1S 1 (combination) 1Oxaliplatin 1Nivolumab 1Irinotecan 1Indocyanine Green 1Gastrectomy 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gastric Adenocarcinoma × Oxaliplatin × Clear all
NCT02862535 2020-12-24

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Gilead Sciences

Phase 1 Terminated
36 enrolled 17 charts
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡